Lyell Immunopharma, Inc. (LYEL)
$14.53-$0.08 (-0.55%) Today
Lynn Seely - OfficerLynn Seely - OfficerLyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 14 | 16,087 | $246K |
| Grant or award | 7 | 64,750 | |
| Other acquisition / disposition | 4 | 225,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
57 Form 4 filings on record, the earliest from Nov 1, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Lynn Seely - Officer | Open-market sale | Common Stock | 9,589 | $15.54 | $149K | |
| Stephen J. Hill - Officer | Open-market sale | Common Stock | 989 | $15.54 | $15K | |
| Gary K. Lee - Officer | Open-market sale | Common Stock | 1,457 | $15.54 | $23K | |
| Veronica Sanchez Bulis - Officer | Open-market sale | Common Stock | 621 | $14.34 | $9K | |
| Gary K. Lee - Officer | Open-market sale | Common Stock | 131 | $14.34 | $2K | |
| Stephen J. Hill - Officer | Open-market sale | Common Stock | 89 | $14.34 | $1K | |
| Lynn Seely - Officer | Open-market sale | Common Stock | 390 | $14.34 | $6K | |
| Innovative Cellular Therapeutics Holdings Ltd - 10% Owner | Other | Common Stock | 44,000 | $0.00 | - | |
| Innovative Cellular Therapeutics Holdings Ltd - 10% Owner | Other | Common Stock | 38,500 | $0.00 | - | |
| Innovative Cellular Therapeutics Holdings Ltd | Open-market sale | Common Stock | 10 | $13.70 | $137 | |
| Innovative Cellular Therapeutics Holdings Ltd | Open-market sale | Common Stock | 10 | $13.73 | $137 | |
| Innovative Cellular Therapeutics Holdings Ltd | Other | Common Stock | 76,000 | $0.00 | - | |
| Innovative Cellular Therapeutics Holdings Ltd | Other | Common Stock | 66,500 | $0.00 | - | |
| Lynn Seely - Officer | Open-market sale | Common Stock | 388 | $18.91 | $7K | |
| Gary K. Lee - Officer | Open-market sale | Common Stock | 130 | $18.92 | $2K | |
| Stephen J. Hill - Officer | Open-market sale | Common Stock | 89 | $18.92 | $2K | |
| Veronica Sanchez Bulis - Officer | Open-market sale | Common Stock | 217 | $18.91 | $4K | |
| William Jl Rieflin | Grant or award | Option (right to buy) | 9,250 | $0.00 | - | |
| Sumant Ramachandra | Grant or award | Option (right to buy) | 9,250 | $0.00 | - | |
| Elizabeth G. Nabel | Grant or award | Option (right to buy) | 9,250 | $0.00 | - | |
| Richard Klausner | Grant or award | Option (right to buy) | 9,250 | $0.00 | - | |
| Cathy Friedman | Grant or award | Option (right to buy) | 9,250 | $0.00 | - | |
| Otis W. Brawley | Grant or award | Option (right to buy) | 9,250 | $0.00 | - | |
| Mark Bachleda | Grant or award | Option (right to buy) | 9,250 | $0.00 | - | |
| David Shook - Officer | Open-market sale | Common Stock | 1,977 | $12.64 | $25K | |
| Smital Shah - Officer | Grant or award | Option (right to buy) | 140,000 | $0.00 | - | |
| ARCH Venture Partners IX, LLC - 10% Owner | Open-market purchase | Common Stock | 488,090 | $25.61 | $12.50M | |
| ARCH Venture Fund XIII, L.P. - 10% Owner | Open-market purchase | Common Stock | 488,090 | $25.61 | $12.50M | |
| Lynn Seely - Officer | Open-market sale | Common Stock | 7,455 | $23.39 | $174K | |
| Stephen J. Hill - Officer | Open-market sale | Common Stock | 1,236 | $23.39 | $29K |
Lyell Immunopharma, Inc. (LYEL) had 25 insider filings in the last 90 days, with the most recent on 2026-08-25. The full record for LYEL runs to 57 Form 4 filings, the earliest from 2024-11-01. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of LYEL were filed in the last 90 days. 3 purchases are on record for this company.
14 insider sales of LYEL were filed in the last 90 days, totaling $246K.
This page tracks LYEL Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add LYEL to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
